Trial Profile
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trametinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 07 Jun 2022 Primary endpoint has been met. (Progression-Free Survival (PFS), as per Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology